Exhibit 4.1


 


THE
WARRANT EVIDENCED HEREBY, AND THE SECURITIES ISSUABLE HEREUNDER, HAVE BEEN AND WILL BE ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES
ACT OF 1933 AS AMENDED, OR THE APPLICABLE SECURITIES LAWS OF ANY STATE. SUCH SECURITIES HAVE BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION
OR RESALE, AND SHALL NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS THE PROPOSED DISPOSITION IS THE SUBJECT OF A CURRENTLY
EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION
IS AVAILABLE, OR, AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER OF THIS WARRANT AND ITS COUNSEL,
PROVIDES THAT SUCH REGISTRATION IS NOT REQUIRED. SEE SECTION 10.


 


	Warrant to Purchase Stock
	 
	Name of Company:	 	Augmedix, Inc., a Delaware corporation
	Number of Warrant Shares:  	 	392,700 (or such lesser amount specified below), subject to adjustment as provided herein
	Class/Series of Stock:	 	Common stock, par value [$0.001] per share
	Exercise Price:  	 	$3.00 per share, subject to adjustment as provided herein
	Original Issue Date:	 	March 24, 2021
	Expiration Date:    	 	The earlier of (1) the date that is ten (10) years after the Original Issue Date, and (2) the third anniversary of the Company’s listing on Nasdaq


 


This
Warrant to Purchase Stock (the “Warrant”) certifies that, for value received, Eastward Fund Management, LLC
(together with any successor or permitted assignee or transferee of this Warrant, “Holder”) is entitled to
purchase up to the above-stated number of fully paid and non-assessable Warrant Shares of the above-stated Class/Series of Stock
from the Company at the Exercise Price at any time or from time to time prior to the Expiration Date, subject to the provisions
and upon the terms and conditions set forth in this Warrant.


 


Notwithstanding
the Number of Warrant Shares referenced above, the Holder shall be entitled to exercise only up to 346,500 of the Warrant Shares
until such time as the Second Advance (as such term is defined in that certain Loan and Security Agreement dated as of March 31,
2021 (the “Loan Agreement”) between initial Holder as lender and Company and Company’s subsidiary, Augmedix
Operating Corporation as co-borrowers) is made (subject to adjustment as provided herein in the same manner as the Number of Warrant
Shares specified above).


 






     


     


    

 


		1.	Exercise
of Warrant.


 


The
Holder may exercise this Warrant, in whole or in part, at any time prior to 5:00 p.m. on the Expiration Date by surrendering
it (with the subscription form at the end of this Warrant duly executed and indicating the whole number of Warrant Shares
with respect to which the Holder shall then be exercising this Warrant) at the principal office of the Company at the time of exercise,
and, unless the Holder is converting this Warrant pursuant to Section 2, together with a certified, registered or bank
cashier’s check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment
acceptable to the Company (hereinafter, the term “Payment” shall mean payment in this manner) for the
aggregate Exercise Price for the Warrant Shares being purchased. Within thirty (30) days after such exercise of this Warrant,
in whole or in part and the Company receives payment of the aggregate Exercise Price or this Warrant is exercised in whole or
in part pursuant to the Conversion Right, the Holder shall receive: (i) a certificate or certificates in the name of the
Holder for the number of whole Warrant Shares to which the Holder shall then be entitled; (ii) cash equal in value to any
fractional share to which the Holder shall then be entitled (with the amount of such cash to be calculated in such reasonable
manner as the Board of Directors of the Company (the “Board”) shall determine); and (iii) if
this Warrant shall not have been fully exercised and shall not have expired, a new warrant of like tenor representing the
Warrant Shares not so acquired. No fractional shares shall be issued to the Holder in respect of any exercise of this
Warrant.


 


	 	2.	Conversion Right.


 


(A) In
lieu of Payment of the aggregate Exercise Price in the manner specified in Section 1 above, the Holder shall have the right (but
not the obligation), to require the Company to convert this Warrant, in whole or in part, into Warrant Shares (the “Conversion
Right”) as provided for in this Section 2. Upon exercise of the Conversion Right, the Company shall deliver to the Holder
(without any Payment by the Holder) that number of Warrant Shares equal to the quotient obtained by dividing (x) the value of
this Warrant at the time the Conversion Right is exercised, by (y) the Fair Market Value of one Warrant Share upon the exercise
of the Conversion Right. For purposes of this Section, the “value” of this Warrant shall be determined by subtracting
the aggregate Exercise Price for the Warrant Shares being converted from the aggregate Fair Market Value of the Warrant Shares
being converted (as determined upon the exercise of the Conversion Right). If such quotient shall include any fraction of a Warrant
Share, then in lieu of such fraction the Company shall deliver to the Holder cash equal in value to such fractional share (determined
in the manner specified in Section 1 above).


 


(B) The
Conversion Right may be exercised by the Holder on any business day prior to 5:00 p.m. on the Expiration Date by delivering this
Warrant, with the subscription form at the end of this Warrant to the Company duly executed, indicating that the Holder is exercising
the Conversion Right and specifying the total number of Warrant Shares with respect to which the Holder is exercising the Conversion
Right.


 


(C)
Fair Market Value of one Warrant Share as of a particular date (the “Determination Date”) shall
mean:


 


(i) If
shares of the Class/Series of Stock for which this Warrant is exercisable are then traded or quoted on a nationally recognized
securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”), then the
Fair Market Value shall be the closing price of a share of the Class/Series of Stock on the Determination Date. If the decision
to sell takes place after market close (4pm ET), then price will be the closing price of the next trading day; or


 



    2


     


    

 


(iii) If
shares of the Class/Series of Stock for which this Warrant is exercisable are not then traded in a Trading Market, then the Fair
Market Value shall be the fair value as reasonably determined in good faith by the Board or a duly appointed committee of the
Board (which determination shall be final and shall be reasonably described in a written notice delivered to the Holder together
with the certificates for the Warrant Shares).


 


3. Reservation
of Warrant Shares; No Restrictions. The Company shall, at all times during the term of this Warrant, reserve a sufficient
number of shares of the Class/Series of Stock for which this Warrant is exercisable to permit the full exercise of this Warrant.
All securities and other property issuable upon exercise or conversion of this Warrant shall be free and clear of all restrictions
upon sale or transfer, except (a) such as may exist under the Company’s Certificate of Incorporation and Bylaws as constituted
on the date of this Warrant; (b) such as may exist or arise under agreements between the Holder, on the one hand, and the Company
or others, on the other hand, with respect to the securities of the Company; and (c) such as may be imposed by applicable securities
laws.


 


4. Adjustments
to the Warrant Shares and Exercise Price. The rights of the Holder shall be subject to the following terms and conditions:


 


(A) Adjustments
for Subdivision or Combination. If the Company at any time or from time to time after the Original Issue Date subdivides (by
any stock split, stock dividend, recapitalization or otherwise) the outstanding shares of the Class/Series of Stock issuable upon
exercise hereof into a greater number of shares, the Exercise Price in effect immediately before that subdivision shall be proportionately
decreased and the number of Warrant Shares shall be proportionately increased. If the Company at any time or from time to time
after the Original Issue Date combines (by reverse stock split or otherwise) the outstanding shares of the Class/Series of Stock
issuable upon exercise hereof, the Exercise Price in effect immediately before the combination shall be proportionately increased
and the number of Warrant Shares shall be proportionately decreased. Any adjustment under this paragraph shall become effective
at the close of business on the date the subdivision or combination becomes effective.


 


(B) Adjustments
for Certain Dividends and Distributions. In the event that at any time or from time to time after the Original Issue Date
the Company shall make or issue, or fix a record date for the determination of holders of the Class/Series of Stock issuable upon
exercise hereof who are entitled to receive a dividend or distribution payable in additional shares of the Class/Series of Stock
or other securities or property (other than cash), then and in each such event, unless such dividend or distribution results in
an adjustment of the Exercise Price pursuant to Section 4(A), provision shall be made so that the Holder shall receive upon exercise
hereof in addition to the securities receivable hereupon, the amount of securities and property, as applicable, of the Company
that the Holder would have received had this Warrant been exercised on the date of such event and had Holder thereafter, during
the period from the date of such event to and including the exercise date, retained such securities receivable by Holder as aforesaid
during such period, giving application during such period to all adjustments called for herein.


 






    3


     


    

 


(C) Adjustment
for Reclassification, Exchange or Substitution. In the event that at any time or from time to time after the Original
Issue Date, the Class/Series of Stock issuable upon the exercise of this Warrant shall be changed into the same or a
different number of shares of any other class or classes (or series) of stock or other securities or property, whether by
capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares or stock dividend
or distribution provided for above, or a merger, consolidation, or sale of assets provided for below), then and in each such
event the Holder shall have the right thereafter to exercise this Warrant for the kind and amount of shares of stock and
other securities and property receivable upon such reorganization, reclassification, or other change, by holders of the
number of shares of the Class/Series of Stock for which this Warrant was exercisable immediately prior to such
reorganization, reclassification, or change, all subject to further adjustment as provided herein.


 


(D) No
Impairment. The Company shall not, by amendment of its Certificate of Incorporation, as in effect on the date hereof, or Bylaws
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder
by the Company but shall at all times in good faith assist in the carrying out of all the provisions of this Section 4 and in
the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment.


 


(E) Notice
of Adjustment of Number of Shares. Upon any adjustment, readjustment or other change relating to the number of Warrant Shares
purchasable upon exercise of this Warrant or to the Exercise Price, then, and in each such case, the Company shall give written
notice thereof, by first class mail, postage prepaid, addressed to the Holder at the Holder’s address as shown on the books
of the Company, which notice shall state the Exercise Price resulting from such adjustment and the number of Warrant Shares (or
other securities or property) purchasable at the Exercise Price upon the exercise of this Warrant setting forth in reasonable
detail the method of calculation and the facts upon which such calculation is based.


 


(F) Waiver
of Adjustment of Exercise Price. Notwithstanding anything herein to the contrary, the operation of, and any adjustment of
the Exercise Price pursuant to, this Section 4 may be waived, either prospectively or retroactively and either generally or in
a particular instance, in each case by the Holder. Any waiver pursuant to this Section 4 shall bind all future holders of this
Warrant.


 


	 	5.	Treatment of Warrant at Acquisition.


 


(A) In
the event that at any time or from time to time after the Original Issue Date, the Company shall merge or consolidate with or
into another entity (other than a merger or consolidation effected exclusively to change the Company’s domicile) or
sell all or substantially all of its assets (an “Acquisition”) in which the consideration to be received
by the Company’s stockholders (in the case of a sale of assets, upon distribution) consists solely of cash, solely of
Marketable Securities or a combination of cash and Marketable Securities, and the fair market value of one Warrant Share as
determined in accordance with Section 2(C) above would be greater than the Exercise Price in effect on such date immediately
prior to such Acquisition (a “Liquid Acquisition”), and Holder has not exercised this Warrant pursuant to
Section 1 above as to all Warrant Shares, then, unless the Holder shall have elected otherwise prior to the consummation of
such Liquid Acquisition, this Warrant shall automatically be converted pursuant to Section 2 above as to all Warrant Shares,
which conversion shall be effective immediately prior to and contingent upon the consummation of such Liquid Acquisition.
Notwithstanding the foregoing, upon the closing of an Acquisition in which the fair market value of one Warrant Share as
determined in accordance with Section 2(C) above is less than the Exercise Price in effect on such date immediately prior to
such Acquisition, and Holder has not exercised this Warrant pursuant to Section 1 above as to all Warrant Shares, provided
that the Company shall have provided to Holder not less than ten (10) days notice of such Acquisition, then this Warrant
shall automatically expire effective immediately prior to and contingent upon the consummation of such
Acquisition.


 






    4


     


    

 


(B) Upon
the closing of any Acquisition other than a Liquid Acquisition, the acquiring, surviving or successor entity shall assume the
obligations of this Warrant, and this Warrant shall thereafter be exercisable for the kind and amount of shares of stock or other
securities or property to which a holder of the number of shares of the class of securities of the Company deliverable upon exercise
of this Warrant would have been entitled upon such Acquisition; and, in such case, appropriate adjustment (as determined in good
faith by the Board) shall be made in the application of the provisions set forth in Section 4 with respect to the rights and interest
thereafter of the Holder, to the end that the provisions set forth in Section 4 (including provisions with respect to changes
in and other adjustments of the Exercise Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to
any shares of stock or other property thereafter deliverable upon the exercise of this Warrant.


 


(C) As
used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements: (i)
the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other
information under the Act (as defined below) and the Exchange Act; (ii) the class and series of shares or other security of the
issuer that would be received by the Holder in connection with the Acquisition were the Holder to exercise this Warrant on or
prior to the closing thereof is then traded in a Trading Market, and (iii) following the closing of such Acquisition, the Holder
would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received
by the Holder in such Acquisition were the Holder to exercise this Warrant in full on or prior to the closing of such Acquisition,
except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations,
and (y) does not extend beyond six (6) months from the closing of such Acquisition.


 


6. Notice
of Certain Events. In case at any time: (1) the Company shall pay any dividend or make any distribution (other than
regular cash dividends from earnings or earned surplus paid at an established rate) to the holders of the Class/Series of
Stock issuable upon exercise of this Warrant (or securities issuable upon conversion or exchange of such securities); (2) the
Company shall offer for subscription pro rata to the holders of the Class/Series of Stock issuable upon exercise of this
Warrant (or securities issuable upon conversion or exchange of such securities) any additional shares of stock of any class
or other rights; (3) there shall be any capital reorganization or reclassification of the capital stock of the Company, or
consolidation or merger of the Company with or sale of all or substantially all of its assets to another entity; or (4) there
shall be a voluntary or involuntary dissolution, liquidation or winding up of the Company; then, in any one or more of such
cases, the Company shall give written notice, to the Holder at Holder’s address as shown on the books of the Company of
the date on which (a) the books of the Company shall close or a record date shall be fixed for determining the stockholders
entitled to such dividend, distribution or subscription rights, or (b) such reorganization, reclassification, consolidation,
merger, sale, dissolution, liquidation or winding up shall take place, as the case may be. Such notice shall also provide
reasonable details of the proposed transaction and specify the date as of which the holders of record of the Class/Series of
Stock issuable upon exercise of this Warrant (or securities issuable upon conversion or exchange of such securities) shall
participate in such dividend, distribution or subscription rights, or shall be entitled to exchange their securities for
securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale,
dissolution, liquidation or winding up, as the case may be. Such written notice shall be given at least 5 days prior to the
action in question and not less than 5 days prior to the record date or the date on which the Company’s transfer books
are closed in respect thereto.


 






    5


     


    

 


	 	7.	Term; Automatic Conversion
    Upon Expiration.


 


(A) Term.
Subject to the provisions of Section 5 above, this Warrant is exercisable in whole or in part at any time and from time to time
on or before 5:00 PM on the Expiration Date and shall be void thereafter.


 


(B) Automatic
Conversion upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Warrant Share as determined
in accordance with Section 2(C) above is greater than the Exercise Price in effect on such date, then this Warrant shall, without
any action by the Holder, be deemed on and as of such date to be automatically exercised pursuant to Section 2 above as to all
Warrant Shares for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver
a certificate representing the Warrant Shares issued upon such exercise to Holder.


 


8. Financial
Statements and other Information. The Company shall furnish the Holder: (A) (as to itself and its subsidiaries): (i)
within one hundred eighty (180) days after the end of each fiscal year of the Company, financial statements, prepared in
accordance with United States generally accepted accounting principles (“GAAP”), all in reasonable detail
and audited by independent certified public accountants of recognized standing selected by the Company; and (ii) within forty
(40) days after the end of each quarter of the Company’s fiscal year, a balance sheet as at the end of such quarter,
and the related statements of income, retained earnings and cash flows for such quarter, prepared by the Company in
accordance with GAAP in a form reasonably acceptable to the Holder; and (B) promptly upon the filing thereof, a true and
correct copy of any amendment, modification, rescission or revocation of the Company’s Certificate of Incorporation. In
the event that Borrower becomes subject to the reporting requirements under the Exchange Act, the Company’s obligations
under subsection (A) hereof may be satisfied by the Company furnishing Holder with copies of the Company’s 10-K’s
and 10-Q’s filed by Borrower with the SEC, any Governmental Authority, any securities exchange or any self-regulatory
organization succeeding to any or all of the functions of the SEC (as such terms are defined in the Loan Agreement), as the
case may be, within the time frame required by such subsection (A). Documents required to be delivered pursuant to the terms
hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered
electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such
documents, or provides a link thereto, on Borrower’s website on the Internet at Borrower’s website address;
provided, however, Borrower shall promptly notify Lender in writing (which may be by electronic mail) of the posting of any
such documents.


 






    6


     


    

 


9. Representations
and Covenants of the Company. The Company represents and warrants to, and agrees with, the Holder that: (A) the initial Exercise
Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the Company Common
Stock or options to purchase shares of Company Common Stock were last sold and issued prior to the Issue Date hereof, (B) the
shares of the Class/Series of Stock represented by each and every certificate for Warrant Shares delivered upon exercise of this
Warrant shall, at the time of such delivery, be duly authorized, validly issued and outstanding, and fully paid and nonassessable,
(C) the Company shall take any and all actions as may be necessary to ensure that the par value or stated value, if any, of each
Warrant Share is at all times equal to or less than the then Exercise Price; and (D) the Company will pay when due and payable
any and all stamp, original issue or similar taxes that may be payable in respect of issuance of any Warrant Shares or certificates
for Warrant Shares.


 


10. Restrictions
upon Transfer. Each Holder acknowledges that this Warrant and the Warrant Shares have not been registered under the Securities
Act of 1933, as amended (the “Act”), and agrees not to sell, pledge, distribute, offer for sale, transfer or
otherwise dispose of this Warrant or any Warrant Shares issued upon its exercise in the absence of (a) an effective registration
statement under the Act as to the securities to be disposed of and registration or qualification of such securities under any
applicable Blue Sky or state securities law then in effect, or (b) an opinion of counsel, reasonably satisfactory to the Company,
that such registration and qualification are not required. The Company shall not require the Holder to provide an opinion of counsel
if the transfer is to an affiliate of the Holder, provided that any such transferee is an “accredited investor” as
defined in Regulation D promulgated under the Act. Additionally, the Company shall not require an opinion of counsel if there
is no material question as to the availability of Rule 144 promulgated under the Act.


 


Without
limiting the generality of the foregoing, unless the offering and sale of the Warrant Shares to be issued upon the particular
exercise of this Warrant shall have been effectively registered under the Act, the Company shall be under no obligation to issue
the shares covered by such exercise unless and until the Holder shall have executed an investment letter in form and substance
reasonably satisfactory to the Company, including a warranty at the time of such exercise that it is acquiring such shares for
its own account, for investment and not with a view to, or for sale in connection with, the distribution of any such shares in
violation of the Act, in which event the Holder shall be bound by the provisions of the following legend, which shall be endorsed
upon the certificate(s) evidencing the Warrant Shares issued pursuant to such exercise:


 


The
shares represented by this certificate have not been registered under the Securities Act of 1933, as amended (the
“Act”), or any state securities laws and may not be sold, pledged, hypothecated or otherwise transferred unless a
registration statement under the Act is in effect with regard thereto and such sale, pledge, hypothecation or other transfer
is registered or qualified under applicable state law, unless exemptions from such registration and qualification under the
Act and such state law are available ,or, an opinion of counsel in form and substance reasonably satisfactory to the Company
and its counsel, provides that such registration is not required.


 






    7


     


    

 


11. No
Distribution. The Holder of this Warrant, by acceptance hereof, represents and warrants that this Warrant has been acquired
for the Holder’s own account without a view to, or for sale in connection with, a distribution thereof in violation of the
Act. Notwithstanding the foregoing, the Company agrees that the Holder shall have the right to grant participation interests in
this Warrant to its affiliate.


 


12. Accredited
Investor Status. The Holder is an “accredited investor” within the meaning of Regulation D promulgated under the
Act.


 


13. Investment
Experience. The Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk.
The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder
can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge
and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment
in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and
certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the
character, business acumen and financial circumstances of such persons.


 


14. Disclosure
of Information. The Holder is aware of the Company’s business affairs and financial condition and has received or has
had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect
to the acquisition of this Warrant and its underlying securities. The Holder further has had an opportunity to ask questions and
receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities
and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to the Holder or to which the Holder has access.


 


15. Registration
Rights. The Holder shall be entitled, with respect to (i) its Warrant Shares and other securities issued or issuable upon
exercise of this Warrant and (ii) any Common Stock issued as (or issuable upon the conversion, exchange or exercise of any
warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or
in replacement of, the shares referenced in clause (i) above, the registration rights afforded to holders of the
Company’s stock, all as set forth in those certain Registration Rights Agreements dated as of October 5, 2020
(individually and collectively, the “Registration Rights Agreement”). Except as may be otherwise provided in the
Registration Rights Agreement governing such rights, the right to have the Company register such securities pursuant to such
agreement shall be automatically assigned to transferees or assignees of this Warrant or such securities, provided that
immediately following such transfer or assignment, the further disposition of such securities by the transferee or assignee
would be subject to restrictions under the Act.


 


16. Books
of the Company. The Company may treat the Holder of this Warrant as appearing on the Company’s books at any time as the Holder
for all purposes. Upon written request, the Company shall permit any Holder or the duly authorized attorney of such Holder, during
ordinary business hours, to inspect and copy or make extracts from the books showing the registered holders of Warrants.


 






    8


     


    

 


17. Loss,
Theft, Destruction or Mutilation of Warrant. If this Warrant shall be lost, stolen, destroyed, or mutilated, the Company shall
execute and deliver to the Holder at the Holder’s sole expense, a replacement warrant of like date, tenor, and denomination
upon receipt by the Company of (a) evidence reasonably satisfactory to the Company of the occurrence of such event, and (b) (i)
in the event of mutilation, upon surrender and cancellation of this Warrant, or (ii) in the event of loss, theft, or destruction
of this Warrant, of indemnity reasonably satisfactory to the Company.


 


18. Holder
Not Stockholder. This Warrant does not, prior to its exercise, confer upon the Holder any right to vote, or to consent, or
to receive notice, or otherwise to act, as a stockholder of the Company in respect of any matters whatsoever, or confer or impose
upon the Holder any other rights or liabilities of a shareholder of the Company.


 


16. Publicity.
The Company hereby consents to Holder publishing the Company’s name and logo on financial reports that Holder provides to
its limited partners and potential investors.


 


17. Notices
and Other Communications. Any notice or other communication under this Warrant shall be effective and shall be deemed to have
been given if, and only if, the same shall have been given in writing and mailed by first-class mail, postage prepaid, addressed
to:


 


(A) the
Company at 111 Sutter St., Suite 1300, San Francisco, CA 94104, or such other address as the Company may designate in writing
to the Holder, or


 


(B) the
Holder at 432 Cherry Street, West Newton, MA 02465, or such other address as the Holder may designate in writing to the Company.


 


18. Headings.
The headings contained in this Warrant have been inserted as a matter of convenience, do not form part of, and shall not affect
construction of, this Warrant.


 


19. Applicable
Law. This Warrant shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts applicable
to contracts wholly made, accepted and performed within that jurisdiction, without application of principles of conflict of laws.


 


20. Effectiveness.
The date of this Warrant is for reference purposes only. The effective date of this Warrant is such date, not to exceed April
15, 2021 (or such later date approved by the Company in its sole and absolute discretion), upon which the Holder fully funds
the Initial Advance to the Company (as confirmed in writing by the Company) pursuant to the terms and conditions of the Loan
Agreement (the “Funding Condition”). If the Funding Condition shall not have been satisfied or performed as of
April 15, 2021 (or such later date approved by the Company in its sole and absolute discretion), this Warrant shall
automatically terminate without any further action on the part of the Company.


 






    9


     


    

 


IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives
effective as of the Original Issue Date written above.


 


	 	“COMPANY”
	 	 
	 	AUGMEDIX, INC.
	 	 	 
	 	By: 	/s/ Emmanuel
Krakaris
	 	Name:   	Emmanuel Krakaris
	 	 	(Print)
	 	Title: 	Chief Executive Officer


 


	Acknowledged:	 
	 	 
	“HOLDER”	 
	 	 	 
	EASTWARD FUND MANAGEMENT, LLC	 
	 	 	 
	By:	/s/ Dennis P. Cameron	 
	Name:	Dennis Cameron	 
	Title:	Chief Executive Officer	 



 






     


     


    

 


SUBSCRIPTION


 


Date:
____________________


 


	To:	Augmedix,
Inc. (the “Company”)



111
Sutter Street, Suite 1300


San
Francisco, CA 04104


 


(1)   ☐ The undersigned hereby elects to purchase
________ shares of Common stock (the “Shares”) of the Company pursuant to the terms of the attached
Warrant, and tenders herewith payment of the exercise price in full.


 


☐ The undersigned hereby elects to convert this
Warrant with respect to ________ shares of Common stock (the “Shares”) of the Company pursuant to
its Conversion Right set forth in Section 2 of the attached Warrant.

  


(2) Please
issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified
below:


 


________________________


(Name)


 


________________________


________________________


(Address)


 


(3) The
undersigned is aware that the Shares have not been registered under the Securities Act of 1933, as amended (the “Act”),
or any state securities laws. The undersigned understands that the reliance by the Company on exemptions under the Act is predicated
in part upon the truth and accuracy of the statements of the undersigned in this Subscription.


 


The
undersigned represents and warrants that (1) it has been furnished with all information which it deems necessary to evaluate the
merits and risks of the acquisition of the Shares; (2) it has had the opportunity to ask questions concerning the Shares and the
Company and all questions posed have been answered to its satisfaction; (3) it has been given the opportunity to obtain any additional
information it deems necessary to verify the accuracy of any information obtained concerning the Shares and the Company; and (4)
it has such knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of acquiring
the Shares and to make an informed investment decision relating thereto.


 


The
undersigned hereby represents and warrants that it is purchasing the Shares for its own account and not with a view to the sale
or distribution of all or any part of the Shares in violation of the Act.


 






     


     


    

 


The
undersigned understands that because the Shares have not been registered under the Act, it must bear the economic risk of the
investment for an indefinite time and the Shares cannot be sold unless the Shares are subsequently registered under
applicable federal and state securities laws or an exemption from such registration is available.


 


The
undersigned consents to the placing of the legend on its certificate for the Shares in accordance with the terms of the Warrant
and to the placing of a stop transfer order on the books of the Company and with any transfer agents against the Shares until
the Shares may be legally resold or distributed without restriction.


 


	 	EASTWARD FUND MANAGEMENT, LLC
	 	 
	 	 
	 	Signature
	 	 
	 	Print name:	                      



 


	 	 
	 	Date: